Lucas Tramujas

Lucas Tramujas

Auto-generated profile, based on publicly available information

Lucas Tramujas

Research Institute, HCor-Hospital do Coração - São Paulo (SP), Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
IMIsrael Silva Maia
Israel Silva Maia
ACAlexandre Biasi Cavalcanti
Alexandre Biasi Cavalcanti
LTLucas Tramujas
Lucas Tramujas
VVViviane Cordeiro Veiga
Viviane Cordeiro Veiga
JOJúlia Oliveira
Júlia Oliveira
FZFernando Godinho Zampieri
Fernando Godinho Zampieri

9 August 2024 in Atherosclerosis
Verified
Journal Article
Closed access
LTLucas Tramujas
Lucas Tramujas
ANAlleh Nogueira
Alleh Nogueira
NFNicole Felix
Nicole Felix
PSPedro Gabriel Melo de Barros e Silva
Pedro Gabriel Melo de Barros e Silva
AAAlexandre Abizaid
Alexandre Abizaid
ACAlexandre Biasi Cavalcanti
Alexandre Biasi Cavalcanti

23 February 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BTBruno Martins Tomazini
Bruno Martins Tomazini
LTLucas Tramujas
Lucas Tramujas
FMFernando Azevedo Medrado
Fernando Azevedo Medrado
SGSamara Pinheiro Do Carmo Gomes
Samara Pinheiro Do Carmo Gomes
KNKarina Leal Negrelli
Karina Leal Negrelli
ACAlexandre Biasi Cavalcanti
Alexandre Biasi Cavalcanti
Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied. Methods: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19. Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. The primary outcome was the decay rate of the SARS-CoV-2 viral load logarithmic curve within 10 days after randomization. Results: From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log10 within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). There was no difference on bleeding episodes or serious adverse events at 28 days. Conclusions: Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
LTLarissa Teixeira
Larissa Teixeira
NFNicole Felix
Nicole Felix
DNDenilsa D. P. Navalha
Denilsa D. P. Navalha
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
MCMariana R.C. Clemente
Mariana R.C. Clemente
LTLucas Tramujas
Lucas Tramujas
Resumo A furosemida é o diurético mais utilizado para o tratamento de sintomas de sobrecarga de volume em pacientes com insuficiência cardíaca. Dados recentes sugerem que a torsemida pode ser superior à furosemida neste contexto. No entanto, ainda não é claro se isso se traduz em melhores resultados clínicos nesta população. Avaliar se a torsemida é superior à furosemida no contexto da insuficiência cardíaca. Realizamos uma revisão sistemática e metanálise de estudos clínicos randomizados (ECRs) comparando a eficácia da torsemida em comparação com a furosemida em pacientes com insuficiência cardíaca. PubMed, Embase e Web of Science foram as bases de dados pesquisadas em busca de estudos elegíveis. Os desfechos de interesse foram internações por todas as causas, internações por insuficiência cardíaca (IIC), internações por todas as causas cardiovasculares, mortalidade por todas as causas, e melhoria de classe da NYHA. Parâmetros ecocardiográficos também foram avaliados. Foi aplicado um modelo de efeitos aleatórios para calcular as razões de risco (RR) e as diferenças médias (DM) com intervalos de confiança (IC) de 95% e nível de significância de 0,05. Foram incluídos 12 ECRs, envolvendo 4.115 pacientes. A torsemida reduziu significativamente a IIC (RR de 0,60; IC de 95%, 0,43-0,83; p=0,002; I2=0%), internação por causas cardiovasculares (RR de 0,72; IC de 95%, 0,60-0,88; p=0,0009; I2=0%), e melhora da fração de ejeção do ventrículo esquerdo (FEVE) (DM de 4,51%; IC de 95%, 2,94 a 6,07; p<0,0001; I2=0%) em comparação com a furosemida. Não houve diferença significativa no número de internações por todas as causas (RR de 0,93; IC de 95%, 0,86-1,00; p=0,04; I2=0%), mortalidade por todas as causas (RR de 0,98; IC de 95%, 0,87-1,10; p=0,73; I2=0%), melhora da classe NYHA (RR de 1,25; IC de 95%, 0,92-1,68; p=0,15; I2=0%), ou mudança de classe NYHA (DM de -0,04; IC de 95%, -0,24 a 0,16; p=0,70; I2=15%) entre os grupos. A torsemida reduziu significativamente as internações por insuficiência cardíaca e causas cardiovasculares, melhorando também a FEVE.

21 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AAArthur M. Albuquerque
Arthur M. Albuquerque
LTLucas Tramujas
Lucas Tramujas
LSLorenzo R. Sewanan
Lorenzo R. Sewanan
JBJames M. Brophy
James M. Brophy
Background Randomised Evaluation of COVID-19 Therapy (RECOVERY) demonstrated that tocilizumab reduces mortality in hospitalized COVID-19 patients. However, substantial uncertainty remains whether tocilizumab’s effect is similar across clinically relevant subgroups. Whether this uncertainty can be resolved with Bayesian methods is unknown. Design, Setting, Participants, and Interventions RECOVERY was a controlled, open-label, platform UK trial that randomized (1:1) 4116 adults with oxygen saturation 99% and 19% in patients using and not using corticosteroids, respectively. In patients on simple oxygen only, non-invasive ventilation and invasive mechanical ventilation, the probabilities of decreased mortality were 96%, >99% and 77%, respectively. The probabilities for a clinically significant mortality reduction, as assessed by an absolute risk difference > 3% (number needed to treat ≤ 33), were 77%, 96%, 56%, respectively. Sensitivity analyses highlighted the uncertainty and lack of conclusive evidence for tocilizumab’s effect in patients on invasive mechanical ventilation and those without concurrent corticosteroids. Posterior probabilities of benefit for hospital discharge outcome were high and consistent across most subgroups. Conclusions In this Bayesian reanalysis, COVID-19 hospitalized patients exposed to corticosteroids or on non-invasive ventilation have a high probability of a clinically meaningful mortality benefit from tocilizumab. Tocilizumab also likely improves discharge from hospital in most subgroups. Future research should further address if patients on invasive mechanical ventilation can also benefit from tocilizumab.

2 February 2024 in Clinical Nutrition Open Science
Verified
Journal Article
Open access
EAErlon Oliveira de Abreu-Silva
Erlon Oliveira de Abreu-Silva
RMRachel Helena Vieira Machado
Rachel Helena Vieira Machado
BSBianca Rodrigues dos Santos
Bianca Rodrigues dos Santos
FKFlávia Soares Kojima
Flávia Soares Kojima
RSRenato Hideo Nakagawa Santos
Renato Hideo Nakagawa Santos
AMAline Marcadenti
Aline Marcadenti